Next Health just announced its inaugural Longevity Summit in Nashville, complete with leading health experts and the usual press cycle that follows. It's the kind of event that sounds like the future of medicine - cryotherapy, plasma exchange, functional wellness. The problem? Next Health isn't publicly traded. It's a private franchise. You can't buy a piece of this story on any exchange.
That is the real contradiction hiding inside the longevity boom.
Here's what the numbers actually show. Longevity investing hit $8.5 billion in 2024, up 220% from the prior year, across 331 deals. That's not a blip. That's a structural reallocation of capital. Companies like Altos Labs - the cellular rejuvenation darling backed by Jeff Bezos and the Chan Zuckerberg Initiative - have raised north of $3 billion. They are private. You can't touch them.
So what's left for ordinary investors who actually have a brokerage account?
The answer, so far, is a patchwork of overhyped biotechs and dominant incumbents trading at rich multiples. Let's look at the clearest example of what happens when a longevity narrative meets public markets.
Voyager Therapeutics (VYGR) rides the longevity/anti-aging wave on public exchanges. The company develops gene therapies for Alzheimer's and other neurodegenerative diseases - VY1706, a tau-silencing gene therapy, just received FDA IND clearance earlier this year. There's an analyst Buy rating with an $11 price target out there. The headline sounds like a turnaround in the making.
But the fundamentals don't support conviction. Voyager reported a $27.9 million net loss in Q1 2026. Revenue? $2.6 million - a fraction of the $8.79 million analysts expected. The market cap sits between $160 million and $220 million depending on the day. The stock has been range-bound between $0.23 and $8.27 over the past year, which tells you the market is struggling to price it because there's nothing to price. No revenue scale. No cash flow. A pipeline that sounds promising until you remember IND clearance is years away from commercial revenue.
I must admit that I've been puzzled by the analyst community's willingness to slap Buy ratings on companies that generate less revenue than a single mature Next Health franchise location - which, by the way, does $4 million annually at a 74% profit margin and you still can't invest in it.
Then there's the other side of the longevity trade: the actual companies making real money. Novo Nordisk's GLP-1 semaglutide franchise is projected to reach roughly $36 billion in 2026. That's not a pipeline. That's revenue. Morningstar has flagged Novo as undervalued relative to its long-term fair value estimate. But here's the thing - Novo is dominant, and dominant companies don't usually trade at contrarian discounts. You're buying quality, not mispricing.
The structural reality is this: the $8.5 billion flowing into longevity is overwhelmingly going to private biotech ventures and wellness franchises that are inaccessible to retail investors. The publicly traded options are split between pre-revenue biotechs with binary clinical risk (VYGR) and proven monopolists at fair-to-rich valuations (NVO). Neither offers the classic GARP setup - growth at a reasonable price - that makes a contrarian case click.
So what should an investor do?
First, resist the narrative pull. A longevity summit in Nashville is a marketing event, not a market signal. The narrative is loud, but the investable evidence is thin.
Second, if you want longevity exposure, Novo Nordisk or Eli Lilly give you the only publicly available revenue-generating plays in the space. Neither is cheap, but they're the only ones with the one thing that matters: actual cash flow from products people are buying right now.
Third, Voyager and similar pre-revenue longevity biotechs belong on a watchlist, not in a portfolio. The FDA IND clearance is a milestone, not a margin statement. I would reassess if VYGR produces collaboration revenue scale or a pivotal trial readout that shifts the probability of commercial success. Until then, the risk/reward doesn't pass the GARP screen.
The longevity boom is real. The investable opportunities in public markets aren't there yet. Don't let the summit FOMO convince you otherwise.